ProofPoint Biologics

ProofPoint Biologics is a biotechnology company specializing in the development of "caged" or conditionally active biologics to enhance the safety and efficacy of antibody-based therapies. The company's proprietary platform, originated from the laboratory of Professor Kim Janda at Scripps Research, utilizes masking peptides and protease-cleavable linkers to keep therapeutic agents inactive until they reach the tumor microenvironment. By leveraging the specific protease activity present in tumors, ProofPoint's technology aims to minimize systemic off-target toxicities, thereby expanding the therapeutic window for potent oncology treatments. In late 2021, the company was acquired by AstraZeneca to integrate its masking technology into AstraZeneca's broader biologics and oncology portfolio.